UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 53.55B
Enterprise Value 32.77B
Trailing P/E N/A
Forward P/E 19.80
PEG Ratio (5 yr expected) 11.55
Price/Sales (ttm)2.32
Price/Book (mrq)1.44
Enterprise Value/Revenue 31.81
Enterprise Value/EBITDA 6-27.30

Trading Information

Stock Price History

Beta (3Y Monthly) 0.74
52-Week Change 3-31.77%
S&P500 52-Week Change 33.36%
52 Week High 3129.59
52 Week Low 374.31
50-Day Moving Average 381.22
200-Day Moving Average 391.48

Share Statistics

Avg Vol (3 month) 3535.32k
Avg Vol (10 day) 3543.74k
Shares Outstanding 543.85M
Float 40.01M
% Held by Insiders 11.76%
% Held by Institutions 1101.74%
Shares Short (Aug 15, 2019) 42.27M
Short Ratio (Aug 15, 2019) 44.16
Short % of Float (Aug 15, 2019) 45.97%
Short % of Shares Outstanding (Aug 15, 2019) 45.19%
Shares Short (prior month Jul 15, 2019) 42.69M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/2
Last Split Date 3Sep 23, 2009

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -7.69%
Operating Margin (ttm)-9.29%

Management Effectiveness

Return on Assets (ttm)-2.49%
Return on Equity (ttm)-4.59%

Income Statement

Revenue (ttm)1.53B
Revenue Per Share (ttm)35.02
Quarterly Revenue Growth (yoy)-16.00%
Gross Profit (ttm)1.43B
EBITDA -101.5M
Net Income Avi to Common (ttm)-117.7M
Diluted EPS (ttm)-2.70
Quarterly Earnings Growth (yoy)18.60%

Balance Sheet

Total Cash (mrq)1.79B
Total Cash Per Share (mrq)40.73
Total Debt (mrq)1.06B
Total Debt/Equity (mrq)41.31
Current Ratio (mrq)4.62
Book Value Per Share (mrq)58.35

Cash Flow Statement

Operating Cash Flow (ttm)-171.6M
Levered Free Cash Flow (ttm)-241.82M